RxDoctor Payments Data

John Buday, MD

Neurology · Tawas City, MINPI 1326017047

Payments from drug & device makers

$7,164in general payments, 2019–2025

Across 440 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$945
  • Biogen$828
  • Jazz Pharmaceuticals Inc.$504
  • Teva Pharmaceuticals USA, Inc.$482
  • UCB, Inc.$473
  • AstraZeneca$357
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$230%
  • Food & beverage$6,99498%
  • Education$1472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,164 in reported general payments places this provider in the 70th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$36,801
Medicare patients
264
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$119,455
BriviactBrivaracetam40$60,543
Nurtec OdtRimegepant Sulfate30$37,478
Emgality PenGalcanezumab-Gnlm24$29,224
Lacosamide102$6,889
Carbidopa-LevodopaCarbidopa/Levodopa167$6,476
Levetiracetam168$5,758
Divalproex Sodium73$4,513
Carbamazepine50$4,390
Carbamazepine ErCarbamazepine22$3,112
Phenytoin Sodium Extended91$2,875
Sumatriptan Succinate54$2,856
Donepezil Hcl75$1,935
Gabapentin74$1,915
Pyridostigmine Bromide14$1,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$137$119,45516 claims
UCB, Inc.Briviact$473$60,54340 claims
PfizerNurtec Odt$48$37,47830 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$102$1,76714 claims
Upsher-smith Laboratories LLCTopiramate$28$54031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 652 neurology providers in Michigan.

Other neurology in Tawas City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →